Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression

Type-2 Innate Signals Are Dispensable for Skeletal Muscle Regeneration and Pathology Linked to Duchenne Muscular Dystrophy - Science in Vancouver

Immune responses play an integral role in skeletal muscle regeneration. In the genetically inherited muscle disease Duchenne muscular dystrophy (DMD), muscle regeneration is disrupted, leading to chronic inflammation, fibrosis, and early mortality. Previously, it has been suggested that type-2 innate immune cells, particularly eosinophils and their production of IL-4, play an essential role in effective muscle regeneration after acute injury. We…

Dystrophin Expressing Chimeric Cell Therapy Demonstrates Long-Term Safety in Non-Ambulatory Duchenne Muscular Dystrophy

Three patients treated with DT-DEC01 showed improvements in various functional tests, including echocardiography, arm movements, grip strength, and spirometry after 12-24 months of treatment.

Dyne announces new long-term data from DMD clinical trial skipping Exon 51

CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has released new long-term data from the DELIVER trial in individuals amenable to skipping Exon 51.  At the 6-month time point, individuals treated with 20 mg/kg of DYNE-251 every 4 weeks had a mean absolute dystrophin expression of 8.72% of normal (adjusted for muscle content).  Improvements in functional outcomes were also observed through 18 months, in…

Dyne’s DMD trial advances patient mobility and dystrophin expression

The Phase I/II trial sought to establish the impact of DYNE-251 on mobility-related endpoints, seeing an increase over baseline at 12 months.The post Dyne’s DMD trial advances patient mobility and dystrophin expression appeared first on Clinical Trials Arena.

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed a Phase 1/2 study, and the biotech is planning to ...

Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression

Dyne's DYNE-251 demonstrates sustained functional improvement in DMD patients with 8.72% dystrophin expression. FDA accelerated approval submission planned for early 2026.